IARTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INTEGRA LIFESCIENCES HOLDINGS CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$13.45+0.24 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $1.05B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
50.9%−11.2 pts over 5 years
Operating margin
-30.2%−41.2 pts over 5 years
Net margin
-31.6%−41.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +1.5% | +1.6% | +3.6% | +6.4% | |
| Gross profit | -5.7% | -5.0% | -0.5% | +4.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 9.4% | 9.1% | -39.9% | |
| Return on assets | 4.2% | 3.9% | -13.5% | |
| Current ratio | 4.01 | 3.09 | 2.54 | |
| Interest coverage | 4.5× | 2.1× | -5.7× | |
| Inventory turnover | 1.6× | 1.7× | 1.7× | |
| Capex to revenue | 4.8% | 2.8% | 5.0% | |
| Diluted shares | 79M | 85M | 77M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Integra Lifesciences generated $896.62M from operations and spent $795.78M on capital expenditure, dividends and share buybacks. 43% of that went back into the business.
Generated
$896.62M
Used
$795.78M
Capital expenditure$343.08M43%Dividends$00%Share buybacks$452.69M57%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-31.6%
×Asset turnover0.43×
×Equity multiplier2.95×
=Return on equity, FY2025-39.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -31.6% | 0.43× | 2.95× | -39.9% |
| FY2024 | -0.4% | 0.41× | 2.50× | -0.4% |
| FY2023 | 4.4% | 0.40× | 2.26× | 4.0% |
| FY2022 | 11.6% | 0.41× | 2.20× | 10.3% |
| FY2021 | 11.0% | 0.42× | 2.31× | 10.6% |
| FY2020 | 9.8% | 0.40× | 2.36× | 9.1% |
| FY2019 | 3.3% | 0.47× | 2.30× | 3.6% |
| FY2018 | 4.1% | 0.47× | 2.70× | 5.2% |
| FY2017 | 5.4% | 0.47× | 2.79× | 7.2% |
| FY2016 | 7.5% | 0.55× | 2.25× | 9.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$516.47M
- Cash generatingOperating cash flow above zero$50.38M
- Return on assets improvedROA up on the prior year-0.2% → -12.8%
- Earnings backed by cashOperating cash flow above net income$50.38M vs -$516.47M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.17 → 2.54
- No dilutionShare count did not rise77M → 77M
- Gross margin improvedGross margin up on the prior year54.77% → 50.86%
- More efficientAsset turnover rose0.43 → 0.41